Glembatumumab Vedotin

DRUG6 trials

Conditions

Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB PositiveHER2/Neu NegativeMelanomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic gpNMB Expressing Triple Negative Breast Cancer

Early Phase 1

Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer

WithdrawnNCT03473691

University of VirginiaTriple Negative Breast Cancer

Start: 2018-05-01End: 2018-05-01Updated: 2024-12-09

Phase 1

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

WithdrawnNCT03326258

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive +15

Start: 2018-04-20End: 2018-04-20Updated: 2018-07-18

Phase 2

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

TerminatedNCT02302339

Celldex TherapeuticsMelanoma

Start: 2014-11-30End: 2018-10-03Updated: 2019-09-06

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

CompletedNCT02363283

National Cancer Institute (NCI)Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7

Start: 2015-09-16End: 2018-07-02Updated: 2020-08-21

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

CompletedNCT02487979

National Cancer Institute (NCI)Recurrent Osteosarcoma

Start: 2016-02-16End: 2021-12-31Updated: 2022-01-18

Unknown Phase

Individual Patient Expanded Access-Glembatumumab Vedotin

NCT03067935

Celldex TherapeuticsMetastatic gpNMB Expressing Triple Negative Breast Cancer

Updated: 2018-05-21

Journal of Clinical Oncology2021-05-204 citations

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

European Journal of Cancer2019-10-0376 citations

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Journal of Clinical Oncology2017-05-2011 citations

Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma

Cancer Research2016-07-155 citations